• Product Description:

Tysinor is an orally administered systemic prodrug of 5′-deoxy-5-fluorouridine (5′-DFUR) which is converted to 5-fluorouracil. It works as a thymidylate synthase inhibitor. Thymidylate is the necessary precursor of thymidine triphosphate, which is essential for the synthesis of DNA, so that a deficiency of this compound can inhibit cell division. Nuclear transcriptional enzymes can mistakenly incorporate FuTP in place of uridine triphosphate (uTP) during the synthesis of RNA. This metabolic error can interfere with RNA processing and protein synthesis.

  • Product Features:

Product Name TYSINOR-500
Generic Name Capecitabine USP 500 mg
FDA Approved Indications
  • Adjuvant Colon Cancer
  • Metastatic Colorectal Cancer
  • Metastatic Breast Cancer
  • TYSINOR-500 tablet: Each commercial box contains 4X8’s tablets in Alu-Alu blister.
  • TYSINOR-500 tablet: Each commercial box contains 7X8’s tablets in Alu-Alu blister.
Prescribing Information TYSINOR-500 (PDF)